Cold-chain compliance is one of the most overlooked areas of risk for clinics that work with compounded GLP-1 medications. A temperature excursion during shipping or storage can compromise a preparation's potency, sterility, and beyond-use date — even if the vial looks completely normal.

The cold-chain requirements for liquid and lyophilized GLP-1 preparations are meaningfully different. Understanding those differences helps your clinic build the right receiving, storage, and documentation protocols for each formulation type.

Compounded GLP-1 preparations — whether semaglutide, tirzepatide, or other peptide-based formulations — are sterile injectables. They are sensitive to temperature for several reasons:

Protein/peptide degradation: GLP-1 receptor agonists are peptide molecules. Elevated temperatures accelerate the chemical degradation reactions (hydrolysis, oxidation, aggregation) that reduce potency and can generate harmful degradation products.

Microbial growth: Temperature excursions above the labeled storage range can promote microbial growth in preparations that contain preservatives at the lower end of their effective concentration range.

Container integrity: Repeated freeze-thaw cycles can stress the container-closure system, potentially compromising the seal and sterility of the preparation.

BUD validity: The beyond-use date assigned by the compounding pharmacy is only valid if the preparation has been stored under the labeled conditions throughout its life. A temperature excursion can invalidate the BUD even if the date on the label has not passed.

Liquid (aqueous solution) compounded GLP-1 preparations are the most temperature-sensitive format. They require continuous cold-chain management from the moment they leave the compounding pharmacy until they are administered to the patient.

Shipping requirements:

• Must be shipped refrigerated (2–8°C) throughout transit
• Require insulated packaging with validated cold-chain performance (ice packs, gel packs, or dry ice depending on transit time and ambient temperature)
• Transit time must be within the validated performance window of the packaging system
• Temperature monitors (data loggers or time-temperature indicators) should accompany shipments

Storage at the clinic:

• Must be stored refrigerated (2–8°C) immediately upon receipt
• Refrigerator temperature must be monitored and logged continuously
• Preparations must not be frozen — freeze-thaw cycles can cause aggregation and particulate formation
• Preparations must be protected from light if labeled as light-sensitive

Receiving protocol:

• Inspect packaging for signs of temperature excursion (melted ice packs, activated temperature indicators)
• Check temperature monitor data if included
• Document receipt date, condition of packaging, and any temperature concerns
• Contact the pharmacy immediately if a temperature excursion is suspected

Lyophilized (freeze-dried) preparations are more robust than liquid preparations before reconstitution. The removal of water significantly reduces the rate of degradation reactions, making lyophilized preparations less sensitive to brief temperature excursions.

Shipping requirements:

• Many lyophilized preparations can be shipped at ambient temperature (15–25°C) for limited periods, depending on the formulation and the pharmacy's stability data
• Some lyophilized preparations still require refrigerated shipping — always check the pharmacy's labeled storage conditions
• Moisture protection is critical — lyophilized preparations must remain in sealed vials; exposure to humidity can cause the powder to absorb water and begin degrading

Storage at the clinic (before reconstitution):

• Follow the labeled storage conditions — refrigerated or room temperature depending on the formulation
• Protect from moisture and light as labeled
• Do not freeze unless specifically labeled for frozen storage
• Monitor and log storage conditions

After reconstitution:

• Once reconstituted, the preparation becomes an aqueous solution and must be treated like a liquid preparation
• Must be stored refrigerated (2–8°C) immediately after reconstitution
• The post-reconstitution BUD is typically much shorter than the pre-reconstitution BUD — often 14–28 days
• Label the vial with the reconstitution date and post-reconstitution BUD

Despite best efforts, temperature excursions happen. A refrigerator malfunctions, a shipment is delayed, or a vial is accidentally left at room temperature. How your clinic responds to a temperature excursion matters.

Do not assume the preparation is still good. The appearance of a preparation after a temperature excursion is not a reliable indicator of quality. Degraded peptides may look identical to intact peptides.

Contact the compounding pharmacy. The pharmacy that compounded the preparation is the appropriate party to assess whether a temperature excursion has compromised the product. Provide them with the details of the excursion (temperature reached, duration, and conditions).

Document the excursion. Record the details of the excursion, the pharmacy's assessment, and the disposition of the affected preparation. This documentation protects your clinic if questions arise later.

Discard if in doubt. If you cannot confirm that the preparation remained within labeled storage conditions, the safest course is to discard it and reorder. The cost of a discarded vial is far less than the cost of an adverse event or a compliance finding.

Clinics that regularly work with compounded GLP-1 preparations should have a formal cold-chain compliance program that includes:

Standard Operating Procedures (SOPs):

• Receiving and inspection of temperature-sensitive preparations
• Refrigerator temperature monitoring and logging
• Temperature excursion response and documentation
• Reconstitution procedures for lyophilized preparations (including labeling with post-reconstitution BUD)

Equipment:

• Calibrated refrigerators with continuous temperature monitoring
• Temperature data loggers or min/max thermometers
• Backup refrigeration plan in case of equipment failure

Training:

• All staff who handle compounded preparations should be trained on cold-chain requirements
• Training should be documented and refreshed periodically

Vendor qualification:

• Evaluate your pharmacy partner's shipping practices and packaging validation
• Ask for documentation of their cold-chain shipping validation studies
• Confirm they use temperature monitors in shipments

Your pharmacy partner's cold-chain practices directly affect the quality of the preparations you receive. When evaluating a compounding pharmacy, ask:

• What are the labeled storage conditions for your GLP-1 preparations?
• How do you validate your shipping packaging for temperature performance?
• Do you include temperature monitors in shipments?
• What is your protocol if a shipment experiences a temperature excursion?
• Can you provide documentation of your cold-chain shipping validation?

503B outsourcing facilities, which operate under FDA cGMP oversight, are required to have formal cold-chain management programs as part of their quality systems. This provides an additional layer of assurance compared to 503A pharmacies, which may have less formal cold-chain programs.

1. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. 2023 Revision.
2. U.S. Food and Drug Administration. Guidance for Industry: Handling and Retention of BA and BE Testing Samples. FDA, 2004.
3. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. ICH, 2003.
4. Parenteral Drug Association. PDA Technical Report No. 39: Cold Chain Guidance for Medicinal Products. PDA, 2007.
5. U.S. Food and Drug Administration. Pharmaceutical Quality System (ICH Q10). FDA, 2009.

MedClinic Partners connects licensed clinics and 503A pharmacies with vetted 503B supply and USA-made cGMP RUO peptides. Questions about cold-chain compliance? Use the Get Connected form to reach our team.